Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial
| Autor: | W. Wolfgang Fleischhacker, Delphine Hennicken, W. Landsberg, Patricia Dewaele, Jean-Pierre Olié, Wendy Kerselaers, Robert D. McQuade, Jean-Yves Loze, Martti E. Heikkinen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Placebo-controlled study Aripiprazole Quinolones Placebo Gastroenterology Piperazines Body Mass Index Young Adult Double-Blind Method Weight loss Internal medicine medicine Humans Pharmacology (medical) Clozapine Aged Pharmacology Body Weight Middle Aged Psychiatry and Mental health Cholesterol Treatment Outcome Tolerability Chemotherapy Adjuvant Anesthesia Adjunctive treatment Clinical Global Impression Schizophrenia Female medicine.symptom Psychology Weight gain medicine.drug |
| Zdroj: | The international journal of neuropsychopharmacology. 13(8) |
| ISSN: | 1469-5111 |
| Popis: | Clozapine is associated with significant weight gain and metabolic disturbances. This multicentre, randomized study comprised a double-blind, placebo-controlled treatment phase of 16 wk, and an open-label extension phase of 12 wk. Outpatients who met DSM-IV-TR criteria for schizophrenia, who were not optimally controlled while on stable dosage of clozapine for > or =3 months and had experienced weight gain of > or =2.5 kg while taking clozapine, were randomized (n=207) to aripiprazole at 5-15 mg/d or placebo, in addition to a stable dose of clozapine. The primary endpoint was mean change from baseline in body weight at week 16 (last observation carried forward). Secondary endpoints included clinical efficacy, body mass index (BMI) and waist circumference. A statistically significant difference in weight loss was reported for aripiprazole vs. placebo (-2.53 kg vs. -0.38 kg, respectively, difference=-2.15 kg, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|